Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy

Tamara Castillo-Trivino, Ellen M Mowry, Alberto Gajofatto, Dorothee Chabas, Elizabeth Crabtree-Hartman, Bruce A Cree, Douglas S Goodin, Ari J Green, Darin T Okuda, Daniel Pelletier, Scott S Zamvil, Eric Vittinghoff and Emmanuelle Waubant

PLOS ONE, 2011, vol. 6, issue 2, 1-5

Abstract: Background: Multiple sclerosis (MS) patients with breakthrough disease on immunomodulatory drugs are frequently offered to switch to natalizumab or immunosuppressants. The effect of natalizumab monotherapy in patients with breakthrough disease is unknown. Methods: This is an open-label retrospective cohort study of 993 patients seen at least four times at the University of California San Francisco MS Center, 95 had breakthrough disease on first-line therapy (60 patients switched to natalizumab, 22 to immunosuppressants and 13 declined the switch [non-switchers]). We used Poisson regression adjusted for potential confounders to compare the relapse rate within and across groups before and after the switch. Results: In the within-group analyses, the relapse rate decreased by 70% (95% CI 50,82%; p

Date: 2011
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0016664 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 16664&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0016664

DOI: 10.1371/journal.pone.0016664

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().